Bioengineered organs could solve organ shortage in the long term

The company 3D BioLabs (3DB) has achieved a significant milestone in the field of regenerative medicine. According to a recent study published in the Proceedings of the National Academy of Sciences, a novel approach to producing large, bioengineered organs has been presented. The aim is to address the shortage of available organs for transplantation. The research, led by Dr. Joseph P. Vacanti, professor at Harvard Medical School and Mass General Hospital, demonstrates the feasibility of a bioengineered liver replacement system that ensures effective blood supply, cell function and viability.

The centerpiece of the innovation is a 3D-printed device (3DPD) that replicates the natural structure of liver tissue. The design utilizes a fractal architecture to support both vascular anastomoses and hepatocyte function. Embedded portal-venous (PV) channels enable a continuous blood supply, while hepatobiliary (HB) channels ensure the viability of liver cells. Active perfusion in tissue scaffolds increases the availability of oxygen and nutrients, which increases cell density and improves the device’s ability to function as a liver tissue substitute.

Dr. Vacanti said: “We are extremely pleased to reach this pivotal milestone in the development of functioning 3D printed organs, which furthers our mission of solving the long-standing issue of organ transplant shortages. With our recent study, we are one step closer to achieving an engineered alternative to liver transplantation, addressing critical organ shortages and helping patients in need.”

Supported by recent work with large-scale implants in pig models, 3DB’s progress shows a promising direction. The study results mark a decisive step towards a bioengineered solution to the global organ shortage.